Agent for eliminating senescent cells

1. A method for treating a disease in which the disease state is expected to be improved by eliminating senescent cells, comprising administrating an effective amount of an SGLT2 inhibitor to a subject in need thereof.

2. The method according to claim 1 , wherein the SGLT 2 inhibitor is at least one selected from the group consisting of low molecular weight compounds, SGLT2 expression inhibitors, and SGLT2-specific binding substances.

3. The method according to claim 1 , wherein the SGLT 2 inhibitor is at least one selected from the group consisting of canagliflozin, empagliflozin, ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate, ertugliflozin, sotagliflozin, and pharmaceutically acceptable salts thereof.

4. The method according to claim 1 , wherein the SGLT2 inhibitor is administered as a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier.

5. The method according to claim 1 , wherein the disease state is a senescence-related disease.

6. The method according to claim 5 , wherein the senescence-related disease is at least one selected from the group consisting of pulmonary fibrosis, emphysema, skeletal muscle atrophy (sarcopenia), osteoarthritis, dementia, frailty, cancer, glaucoma, age-related macular degeneration, presbyopia, age-related alopecia, age-related hearing loss, pain associated with aging, lumbar pain, joint pain, asteatotic eczema, cutaneous pruritus, fatty liver, nonalcoholic steatohepatitis (NASH), liver cirrhosis, osteoporosis, osteoarthropathy, Hutchinson-Gilford progeria syndrome, Werner syndrome, Cockayne syndrome, and Rothmund-Thomson syndrome.

7. The method according to claim 6 , wherein the senescence-related disease is at least one selected from the group consisting of Hutchinson-Gilford progeria syndrome, Werner syndrome, Cockayne syndrome, and Rothmund-Thomson syndrome.

8. The method according to claim 6 , wherein the senescence-related disease is at least one selected from the group consisting of skeletal muscle atrophy (sarcopenia), dementia, and frailty.

9. The method according to claim 1 , wherein the method selectively reduces or eliminates senescent cells.

10. The method according to claim 9 , wherein the SGLT2 inhibitor is canagliflozin.

11. The method according to claim 1 , wherein the method suppresses an increase of expression of p53, p16 and/or p21.